{"id":2093969,"date":"2023-11-08T13:26:02","date_gmt":"2023-11-08T18:26:02","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/fda-approves-eli-lilly-diabetes-drug-for-weight-loss-creating-rival-for-wegovy\/"},"modified":"2023-11-08T13:30:44","modified_gmt":"2023-11-08T18:30:44","slug":"fda-approves-eli-lilly-diabetes-drug-for-weight-loss-creating-rival-for-wegovy","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/fda-approves-eli-lilly-diabetes-drug-for-weight-loss-creating-rival-for-wegovy\/","title":{"rendered":"FDA approves Eli Lilly diabetes drug for weight loss, creating rival for Wegovy"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"float:left\"><div class=\"counts mashsbcount\">26<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Ffda-approves-eli-lilly-diabetes-drug-for-weight-loss-creating-rival-for-wegovy%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2093969&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><h2>FDA Approves Eli Lilly&#8217;s Diabetes Drug for Weight Loss, Posing\u200b a Strong Challenge to Novo \u2064Nordisk&#8217;s Wegovy<\/h2>\n<p>The Food \u200dand Drug Administration \u200d(FDA) has \u2063given its seal of approval to Eli Lilly \u2062and Company&#8217;s diabetes \u200bdrug, which has now emerged\u2064 as a formidable competitor to \u2062Novo Nordisk&#8217;s Wegovy. This groundbreaking\u200d medication, known as Mounjaro for diabetes management,\u2063 will now be marketed under the name Zepbound.<\/p>\n<h3>Addressing\u2064 a Critical Health Concern<\/h3>\n<blockquote>\n<p>&#8220;Obesity and overweight\u200b are\u200c serious conditions that can be associated with some \u2064of the \u2062leading causes of death such \u2064as heart disease, stroke, and diabetes,&#8221; emphasized Dr. John\u2064 Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA&#8217;s Center for Drug Evaluation and\u2063 Research. &#8220;In light of increasing\u200b rates of both\u2064 obesity and \u2062overweight in the United States, today&#8217;s approval addresses an \u200bunmet medical need.&#8221;<\/p>\n<\/blockquote>\n<p>The FDA revealed that\u200b in clinical trials, individuals\u2062 without diabetes \u2063who received Zepbound experienced an impressive average <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/alexei-navalny-goes-on-hunger-strike-russian-prison-service-responds\/\" title=\"Alexei Navalny Goes On Hunger Strike, Russian Prison Service Responds\">weight loss<\/a> of 18%.<\/p>\n<p><strong>This is a developing\u2064 story.<\/strong><\/p>\n<p> <\/p>\n<h2> How does the approval of Zepbound present \u200da challenge to Novo Nordisk&#8217;s Wegovy\u200d and how does it \u2064contribute to the ongoing competition in the diabetes drug market<\/h2>\n<p><span>  The Food and\u200c Drug Administration (FDA) has recently granted its approval to Eli Lilly \u200cand Company&#8217;s\u200b diabetes drug, presenting a significant challenge\u2062 to Novo Nordisk&#8217;s Wegovy. This groundbreaking medication, originally known as Mounjaro for diabetes management, will now be marketed\u2062 under the name Zepbound.<\/p>\n<p>The approval of Zepbound by the FDA addresses \u200ca critical \u2064health concern related to obesity and overweight.\u2064 Dr. John Sharretts, director of the Division of Diabetes, \u200bLipid Disorders, and Obesity in the FDA&#8217;s Center for Drug Evaluation and Research, emphasized the seriousness of these conditions. He noted that obesity and overweight are associated\u200d with leading causes of death\u200c such as heart disease, \u2062stroke, and diabetes. With increasing rates of obesity\u200c and overweight in the United States, the approval of\u2063 Zepbound serves to \u2063meet an\u2064 unmet medical need.<\/p>\n<p>Clinical trials conducted by the FDA revealed that Zepbound\u2063 demonstrated promising results. Even in individuals without \u2063diabetes, the drug led \u200dto an impressive average weight loss of 18%. This showcases \u2062the potential impact of Zepbound in the fight against obesity and its related health complications.<\/p>\n<p>The approval of Zepbound marks a significant milestone for \u200cEli\u200c Lilly and Company as they secure a formidable position in the diabetes drug\u2062 market. Novo Nordisk&#8217;s\u200c Wegovy, which has previously enjoyed a dominant position,\u2064 now <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/andrew-giuliani-banned-from-appearing-in-person-at-new-york-gop-debate\/\" title=\"Andrew Giuliani Banned From Appearing In-Person At New York GOP Debate\">faces strong competition<\/a> from Eli Lilly&#8217;s Zepbound. The diabetes \u2062drug market is highly \u200dcompetitive, and this latest approval adds\u2062 to the ongoing battle between these pharmaceutical giants.<\/p>\n<p>The development of Zepbound also sheds light on\u2064 the growing emphasis on \u200cinnovative solutions to combat obesity and overweight. As \u2062a major public health concern, the rise in these \u200cconditions necessitates effective and safe medical interventions. Zepbound offers hope\u200c for individuals struggling with weight management and provides healthcare professionals with an additional tool in their \u200darsenal to address\u200b this pressing health issue.<\/p>\n<p>It is worth noting that this story is\u2064 still developing, and further updates may arise \u2062regarding the performance and availability of Zepbound in the market. The FDA approval signifies a <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/another-opioid-reversal-drug-approved-by-fda\/\" title=\"FDA approves new opioid reversal drug.\">significant\u200d step forward<\/a> in the battle \u200dagainst obesity, and the impact of \u200cZepbound on weight loss and overall <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/fda-approves-eli-lilly-diabetes-drug-for-weight-loss-creating-rival-for-wegovy\/\" title=\"FDA approves Eli Lilly diabetes drug for weight loss, creating rival for Wegovy\">health management deserves\u2062 close \u2064attention<\/a>.<\/p>\n<p>In conclusion, the FDA&#8217;s approval of Zepbound as a diabetes \u2062drug with impressive weight\u2062 loss properties poses a strong challenge to Novo Nordisk&#8217;s Wegovy. This development \u2064addresses a critical health\u200b concern,\u2064 and the potential of Zepbound to combat obesity and\u200c overweight is significant. As the <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/moderna-loses-billions-in-value-after-rival-pfizers-vaccine-warning\/\" title=\"Moderna's Value Plummets After Pfizer's Vaccine Warning\">pharmaceutical industry continues<\/a> to strive for innovative solutions in diabetes management, the emergence\u200d of Zepbound marks an important milestone\u2062 in the fight against obesity.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Food and Drug Administration on Wednesday approved Eli Lilly and Company&#8217;s diabetes drug for weight loss, making it a main rival to Novo Nordisk&#8217;s Wegovy. The Lilly drug, which is already approved for diabetes management under the name Mounjaro, will be marketed by the name Zepbound. REPUBLICAN DEBATE: RON DESANTIS FIGHTS ON HOME TURF<\/p>\n","protected":false},"author":1,"featured_media":2093971,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[],"tags":[],"class_list":["post-2093969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2093969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2093969"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2093969\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2093971"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2093969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2093969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2093969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}